Steering the Treatment of Gynecologic Cancers With Biomarkers
Several drug classes, including immunotherapy, antibody-drug conjugates and PARP inhibitors have helped improve outcomes for gynecologic cancers.
Read More
Why Biomarkers Are a ‘Double-Edged Sword’ for Patients and Providers
As part of the CURE® Educated Patient® Gynecologic Cancers Summit, an expert explained the basics of biomarkers and the questions they raise.
Navigating Clinical Trials in Gynecologic Cancers
Patients can benefit from clinical trials in gynecologic cancers, and knowing that they can advocate for themselves for potential consideration for study enrollment.
Pros and Cons of Surgery Approaches in Gynecologic Cancers
Surgery for gynecologic cancers is a common form of treatment, but each surgical approach has its advantages and disadvantages for patients.
Understanding Molecular Classifications of Gynecologic Cancers
After being diagnosed with a type of gynecologic cancer, it is essential for patients to understand the molecular makeup of their disease.
